1. 130P COM701 ± nivolumab: Preliminary results of antitumor activity from a phase I study in patients with metastatic NSCLC who have received prior PD-1/PD-L1 inhibitor. (December 2022) Authors: Sullivan, R.J.; Sharma, M.R.; Vaena, D.; Hamilton, E.; Izar, B.; Rasco, D.; Gainor, J.; D. Shepard, ; Papadopoulos, K.; Dumbrava, E.E.; Adewoye, H.H.; Ferre, P.J.; Ophir, E.; Patel, M.; Patnaik, A.; Chmielowski, B. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 158P Triple blockade of the DNAM-axis with COM701 + BMS-986207 + nivolumab demonstrates preliminary antitumor activity in patients with platinum-resistant OVCA. (December 2022) Authors: Moroney, J.; Yeku, O.; Fleming, G.; Emens, L.A.; Vaena, D.; Dumbrava, E.E.; Rasco, D.; Sharma, M.R.; Papadopoulos, K.; Patnaik, A.; Sullivan, R.J.; Adewoye, H.H.; Ophir, E.; Cojocaru, G.; Ferre, P.J.; Izar, B.; Gaillard, S. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 159P COM701 in combination with nivolumab demonstrates preliminary antitumor activity in patients with platinum-resistant epithelial ovarian cancer. (December 2022) Authors: Yeku, O.; D. Shepard, ; Patel, M.; Fleming, G.; Vaena, D.; Rasco, D.; Chmielowski, B.; Sharma, M.R.; Hamilton, E.; Sullivan, R.J.; Papadopoulos, K.; Izar, B.; Cojocaru, G.; Ophir, E.; Ferre, P.J.; Dumbrava, E.E. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Immunotherapeutic strategies for cutaneous squamous cell carcinoma prevention in xeroderma pigmentosum. (1st November 2019) Authors: Ameri, A.H.; Mooradian, M.J.; Emerick, K.S.; Park, J.C.; Wirth, L.J.; Asgari, M.M.; Tsao, H.; Lawrence, D.; Sullivan, R.J.; Demehri, S. Journal: British journal of dermatology Issue: Volume 181:Number 5(2019) Page Start: 1095 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Immunotherapeutic strategies for cutaneous squamous cell carcinoma prevention in xeroderma pigmentosum. (7th August 2019) Authors: Ameri, A.H.; Mooradian, M.J.; Emerick, K.S.; Park, J.C.; Wirth, L.J.; Asgari, M.M.; Tsao, H.; Lawrence, D.; Sullivan, R.J.; Demehri, S. Journal: British journal of dermatology Issue: Volume 181:Number 5(2019) Page Start: 1095 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Major therapeutic developments and current challenges in advanced melanoma. (1st January 2014) Authors: Sullivan, R.J.; Flaherty, K.T. Journal: British journal of dermatology Issue: Volume 170:Number 1(2014:Jan.) Page Start: 36 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Major therapeutic developments and current challenges in advanced melanoma. (January 2014) Authors: Sullivan, R.J.; Flaherty, K.T. Journal: British journal of dermatology Issue: Volume 170:Number 1(2014:Jan.) Page Start: 36 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Preliminary Clinical Data From Ongoing Phase 2 Study With Enhancer of Zeste Homolog 2 (EZH2) Inhibitor CPI-0209 in Patients With Advanced Solid Tumors or Hematologic Malignancies. (October 2022) Authors: Kindler, H.; Harvey, R.D.; Duska, L.R.; Gandhi, L.; Sullivan, R.J.; Gastinne, T.; Kwiatek, M.; García-Sancho, A.M.; Hadar, N.; Kann, L.; Faulhaber, N.; Drescher, C. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S31 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Response to Letter to the Editor: A review of laminitis in the donkey. (22nd August 2021) Authors: Thiemann, A.; Buil, J.; Rickards, K.; Sullivan, R.J. Journal: Equine veterinary education Issue: Volume 34:Number 11(2022) Page Start: 616 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Serum lactate dehydrogenase is a more useful biomarker of prognosis than serum S100B in patients with BRAF‐mutant melanoma. (1st April 2016) Authors: Sullivan, R.J. Journal: British journal of dermatology Issue: Volume 174:Number 4(2016) Page Start: 716 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗